Unjoni Ewropea - Franċiż - EMA (European Medicines Agency)

vbi vaccines b.v. - antigène de surface de l'hépatite b - hépatite b - vaccins - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 8 mg, ethanolum anhydricum 15.31 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.16 ml. - substitution en cas de dépendance aux opiacés - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 16 mg, ethanolum anhydricum 30.62 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.32 ml. - substitution en cas de dépendance aux opiacés - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 24 mg, ethanolum anhydricum 45.94 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.48 ml. - substitution en cas de dépendance aux opiacés - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 32 mg, ethanolum anhydricum 61.25 mg, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.64 ml. - substitution en cas de dépendance aux opiacés - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 64 mg, n-methylpyrrolidonum, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.18 ml. - substitution en cas de dépendance aux opiacés - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 96 mg, n-methylpyrrolidonum, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.27 ml. - substitution en cas de dépendance aux opiacés - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

future health pharma gmbh - buprenorphinum - depot-injektionslösung - buprenorphinum 128 mg, n-methylpyrrolidonum, phosphatidylcholinum ex soja, glyceroli dioleas, ad solutionem pro 0.36 ml. - substitution en cas de dépendance aux opiacés - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

lundbeck (schweiz) ag - aripiprazolum - depot-injektionssuspension - praeparatio cryodesiccata: aripiprazolum 300 mg ut aripiprazolum monohydricum, carmellosum natricum, mannitolum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, pro vitro corresp. natrium max. 1.6 mg. solvens (i.m.): aqua ad iniectabile pro vitro. corresp. in solutione recenter reconstituta 200 mg pro 1 ml. - neuroleptiques - synthetika

Svizzera - Franċiż - Swissmedic (Swiss Agency for Therapeutic Products)

lundbeck (schweiz) ag - aripiprazolum - depot-injektionssuspension - praeparatio cryodesiccata: aripiprazolum 400 mg ut aripiprazolum monohydricum, carmellosum natricum, mannitolum, natrii dihydrogenophosphas monohydricus, natrii hydroxidum, pro vitro corresp. natrium max. 2.2 mg. solvens (i.m.): aqua ad iniectabile pro vitro. corresp. in solutione recenter reconstituta 200 mg pro 1 ml. - neuroleptiques - synthetika